NCT04712864 - Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions

T-Cell LymphomaPeripheral T-Cell Lymphoma RefractoryCutaneous T-Cell Lymphoma RefractoryCutaneous T-Cell Lymphoma RecurrentPeripheral T-Cell Lymphoma Recurrent

Interventions

BIOLOGICAL

LB1901

LB1901 - an autologous CD4-targeted CAR-T immunotherapy

Trial Locations (4)

53226

Medical College of Wisconsin, Milwaukee

55905

Mayo Clinic, Rochester

77030

MD Anderson Cancer Center, Houston

98195

Fred Hutchinson Cancer Research Center, Seattle